Skip to content

The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: a randomized controlled trial.

The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: a randomized controlled trial.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032611
Enrollment
Unknown
Registered
2020-05-04
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2DM

Interventions

Sponsors

The Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Participants are 65-85 years old. (2) Meet the diagnostic criteria for type 2 diabetes. (3) The BMI is between 18 kg / m2 and 28 kg / m2. (4) Blood biochemical indicators such as liver and kidney function are normal. (5) Accept and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Glycated hemoglobin is greater than 10%. (2) Diabetes is in the period of acute complications, such as diabetic ketoacidosis, diabetic hyperosmolar nonketotic coma, hypoglycemic coma or severe unconscious hypoglycemia. (3) Diabetic patients with severe chronic complications, such as diabetic foot with infection, diabetic nephropathy with renal insufficiency, diabetic retinopathy of more than 3 stages, etc. (4) Patients with anxiety, depression, mania, or other mental illness. (5)Patients with a history of stroke, transient ischemic attack, unstable angina, and myocardial infarction in the first 6 months of the study were patients with congestive heart failure. (6) A history of acute or chronic pancreatitis. (7) Allergic to Chinese herbal medicine. (8) The history of the use of immunosuppressants and glucocorticoids in the past three months. (9) Involuntary ability and other diseases affecting glucose metabolism. (10) Patients who were enrolled in other clinical tests in the past three months.

Design outcomes

Primary

MeasureTime frame
standard deviation of blood glucose level;coefficient of variation;

Secondary

MeasureTime frame
mean blood glucose;largest amplitude of glycemic excursions;Postprandial glycemic excursions;glycated hemoglobin;

Countries

China

Contacts

Public ContactQiu Chen

The Hospital of Chengdu University of Traditional Chinese Medicine

chenqiu1005@cdutcm.edu.cn+86 18981885702

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026